908117-02-2Relevant academic research and scientific papers
Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents
Huang, Kenneth H.,Veal, James M.,Fadden, R. Patrick,Rice, John W.,Eaves, Jeron,Strachan, Jon-Paul,Barabasz, Amy F.,Foley, Briana E.,Barta, Thomas E.,Ma, Wei,Silinski, Melanie A.,Hu, Mei,Partridge, Jeffrey M.,Scott, Anisa,DuBois, Laura G.,Freed, Tiffany,Steed, Paul M.,Ommen, Andy J.,Smith, Emilie D.,Hughes, Philip F.,Woodward, Angela R.,Hanson, Gunnar J.,McCall, W. Stephen,Markworth, Christopher J.,Hinkley, Lindsay,Jenks, Matthew,Geng, Lifeng,Lewis, Meredith,Otto, James,Pronk, Bert,Verleysen, Katleen,Hall, Steven E.
experimental part, p. 4288 - 4305 (2010/01/16)
A novel class of heat shock protein 90 (Hsp90) inhibitors was developed from an unbiased screen to identify protein targets for a diverse compound library. These indol-4-one and indazol-4-one derived 2-aminobenzamides showed strong binding affinity to Hsp
Tetrahydroindole and Tetrahydroindazole Derivatives
-
Page/Page column 40, (2008/12/04)
The invention provides indole and indazole compounds of Formula (I) or pharmaceutically acceptable salts thereof which are useful for treating and/or preventing diseases and/or disorders ameliorated by the inhibition of Heat-Shock Protein 90. The invention further provides pharmaceutical compositions comprising compounds of Formula (I) and methods of preparing compounds of Formula (I).
TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES
-
Page/Page column 112-114, (2008/06/13)
Disclosed are compounds and pharmaceutically acceptable salts of Formula (I): wherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4 are as defined
